Case (age/sex) | Pathology | Immunofluorescence | IgG | anti-GBM antibodies | Electron microcopy |
---|---|---|---|---|---|
31/M | Proliferative basement membranes, focal crescents, and mesangial proliferation. | IgG (+); IgA (+); IgM (+); C3 (-); C1q (-); Fib (-); ALB (-); kappa (+); and lambda (+). | linear deposition | Negative | No electron-dense deposits and presence of foot process fusion. |
57/F [20] | Mesangial proliferation, and focal crescents. | IgG (+); IgA (+); IgM (-); C3 (+); C1q (-); kappa (+); and lambda (+). | linear deposition | Negative | No electron-dense deposits and extensive FPE. |
53/M [21] | Proliferative basement membranes, focal crescents, and segmental nodular glomerulosclerosis | IgG1 (+); IgG4 (+). | linear deposition | Negative | Fibrillar deposition. |
74/M [22] | Mesangial proliferation, no crescents, and thinning basement membranes | IgG1 (+);IgG4 (+);IgG2 (+); kappa (+); and lambda (+). | linear deposition | Negative | Accumulation of flocculent debris. |
43/F [23] | Focal crescents and endocapillary hypercellularity | IgG (+); IgA (-); IgM (-); C3 (-); C4 (-); C1q (-); IgG1 (+);IgG4 (+); IgG2 (-);IgG3 (-); kappa (+); and lambda (+). | linear deposition | Negative | Some FPE |
13/F [24] | Mesangial proliferation, focal crescents, some globally or segmentally sclerosed glomeruli | IgG (+); IgA (+); IgM (-); C3 (+);C1q (-); IgG1 (+);IgG4 (+);kappa (+); and lambda (+). | linear deposition | Negative | NA |
4/F [25] | Subtle segmental scars, segmental endocapillary hypercellularity, and cellular crescent | IgG (+);IgA (-); IgM (-); C3 (-); C1q (-). | linear deposition | Negative | No electron-dense deposits |
30/M [26] | Normal | IgG (+);C3 (+);kappa (+); and lambda (+). | linear deposition | Negative | NA |
58/M [27] | Focal crescents and proliferative, and sclerosing glomerulonephritis | IgG (+); IgA (+); kappa (+); and lambda (+). | linear deposition | Negative | NA |
79/M [28] | NA | IgG (+); IgA (+); C3 (+); and lambda (+); fibrinogen (+). | linear deposition | Negative | NA |
48/F [11] | Some globally sclerotic glomeruli, cellular and fibric crescents, Bowman’s capsules and segmental sclerotic glomeruli, tubular atrophy accompanied by interstitial fibrosis, interstitial infiltration of lymphocytes, monocytes, and plasmocytes | IgG (+) | linear deposition | Negative | No electron-dense deposits and presence of foot process fusion. |
37/M [29] | diffuse proliferation in the glomeruli, with increased mesangial proliferation; crescents | IgG (+);C3 (+). | linear deposition | Negative | No electron-dense deposits. |
64/M [30] | Necrotizing glomerulonephritis, cellular crescent, and diffuse segmental endocapillary proliferation. | IgG1-κ (+). | linear deposition | Negative | NA |
69/M [31] | Mesangial proliferation, diffuse endocapillary hypercellularity, mesangiolysis, and extracapillary proliferation | IgG (+); IgG1 (+); IgG2 (+);IgG3 (-); IgG4 (-); | linear deposition | Negative | No electron-dense deposits, diffuse foot process effacement and subendothelial space widening |
70/M [32] | Cellular crescents and necrotic lesions | IgG (+);IgM (-); C3 (-);kappa (+); and lambda (+); fibrinogen (+). | linear deposition | Negative | Proliferative basement membranes |
46/F [12] | Cellular crescents and fibrinoid necrosis. | IgG (+); IgG1 (+); IgG2 (+);IgG3 (-); IgG4 (+). | linear deposition | Negative | Normal |
53/F [33] | Interstitial fibrosis, tubular atrophy, moderate arteriosclerosis, and moderate arteriolar hyalinosis of moderate chronicity | IgG1-kappa (+); IgG1 (+); IgG2 (+);IgG3 (-); IgG4 (+). | linear deposition | Negative | No electron-dense deposits and extensive FPE |
24/M [34] | Cellular crescents and mesangial proliferation, | IgG (+); IgA (+); IgM (-); C3 (-); C1q (-);IgG2 (+); IgG4 (+). | linear deposition | Negative | No electron-dense deposits |
33/M [35] | Mesangial proliferation, focal interstitial fibrosis, and tubular atrophy | IgG (+);C3 (+); C4d (-). | linear deposition | Negative | NA |
37/M [36] | Cellular crescents | IgG (-); IgA (+). | linear IgA deposition | Negative | NA |